GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RemeGen Co Ltd (HKSE:09995) » Definitions » Total Current Liabilities

RemeGen Co (HKSE:09995) Total Current Liabilities : HK$1,244.2 Mil (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is RemeGen Co Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. RemeGen Co's total current liabilities for the quarter that ended in Dec. 2023 was HK$1,244.2

RemeGen Co Total Current Liabilities Historical Data

The historical data trend for RemeGen Co's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RemeGen Co Total Current Liabilities Chart

RemeGen Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Current Liabilities
Get a 7-Day Free Trial 953.58 511.26 754.76 996.45 1,244.22

RemeGen Co Quarterly Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23 Mar24
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 996.45 952.98 - 1,244.22 -

RemeGen Co Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

RemeGen Co's Total Current Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=765.806+377.047
+Other Current Liabilities+Current Deferred Liabilities
=101.365+0
=1,244.2

RemeGen Co's Total Current Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=765.806+377.047
+Other Current Liabilities+Current Deferred Liabilities
=101.365+0
=1,244.2

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

RemeGen Co Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of RemeGen Co's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

RemeGen Co (HKSE:09995) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RemeGen Co Ltd (HKSE:09995) » Definitions » Total Current Liabilities
Comparable Companies
HKSE:09926 HKSE:01877 HKSE:06990 HKSE:01548 HKSE:01530 HKSE:02162 HKSE:06826 HKSE:09969 HKSE:01541 HKSE:09966 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
REGMF:USA REG:Germany 688331:China
Address
58 Middle Beijing Road, Yantai Area of Shandong Pilot Free Trade Zone, Yantai Development Zone, Yantai, CHN
Website
http://www.remegen.com
RemeGen was established in 2008 and listed on the Hong Kong Stock Exchange in 2020. It is a commercial stage biotech company focused on developing drugs to treat autoimmune disease, cancer, and ophthalmic disease for the China market and potentially the global market, as well. Its core assets are disitamab vedotin (RC48), a HER2-targeting antibody-drug conjugate (ADC) for treating HER2-expressing cancers, and telitacicept (RC18), a BLyS and APRIL targeting bispecific fusion protein for treating various B-cell mediated autoimmune diseases. These drugs received their first approvals in China in 2021 and are both covered on the National Reimbursement Drug List (NRDL).
Executives
Yi Fang Da Ji Jin Guan Li You Xian Gong Si 2102 Investment manager
Rongchang Holding Group Ltd. 2103 Interests held jointly with another person
Yantai Rongda Venture Capital Center (limited Partnership) 2103 Interests held jointly with another person
Yang Minhua 2103 Interests held jointly with another person
Xiong Xiaobin 2103 Interests held jointly with another person
Wen Qingkai 2103 Interests held jointly with another person
Wei Jianliang 2103 Interests held jointly with another person
Wang Xudong 2103 Interests held jointly with another person
Wang Weidong 2201 Interest of corporation controlled by you
Wang Liqiang 2103 Interests held jointly with another person
I-nova Limited 2101 Beneficial owner
Lin Jian 2103 Interests held jointly with another person
Fang Jianmin 2103 Interests held jointly with another person
Deng Yong 2103 Interests held jointly with another person
Morgan Stanley 2201 Interest of corporation controlled by you

RemeGen Co (HKSE:09995) Headlines

No Headlines